Aussie company picks up pace

Aussie biotech, Psylo, has joined forces with behavioural neuroscience expert Nick Everett to accelerate the development of their next-generation psychedelics that could enter clinical trials next year.

To see the whole article please log in.

Our old access system is being retired.

Please create a password and click 'Log in' for ongoing access.

Please choose a password to secure your access to Pharma in Focus (minimum 8 characters).

You're here because you requested to reset your password.

Please choose a new password (minimum 8 characters).

To search the News Archive you need to be logged in.

Retype password

Not a member? Sign up here